Patients with melanoma have more promising options than ever with the advent of targeted therapies and immunotherapies, said Mario Lacouture, MD, director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center. His research aims to provide patients the best possible quality of life while taking these treatments, which can often have adverse effects.
Patients with melanoma have more promising options than ever with the advent of targeted therapies and immunotherapies, said Mario E. Lacouture, MD, director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center. His research aims to provide patients the best possible quality of life while taking these treatments, which can often have adverse effects.
Transcript
What are some of the most promising new drugs for treating melanomas?
The most promising drugs to treat melanoma are targeted therapies and immunotherapies. It is important for patients to decide with their doctors based on the mutations in their cancer as well as other features such as the type of infiltrates in their cancer, to decide whether a patient should begin therapy with a targeted therapy or immunotherapy.
How can patients with melanoma maintain or improve their quality of life while on these treatments?
To maintain patients’ quality of life, it is important for patients to be aware of the adverse events that can occur with these therapies. Therefore, it is important to educate patients and to provide frequent follow-up when they are receiving targeted therapies or immunotherapies. In most of these cases, interventions can be conducted, for example, by treating patients’ rashes with topical corticosteroids or antihistamines, or using oral corticosteroids whenever they develop rashes or other toxicities to immunotherapies or targeted therapies.
How has your research helped patients treat their skin-related side effects while not interfering with the effectiveness of the anti-cancer drugs?
Our research focuses on identifying individuals that are at risk for these adverse events, and managing or preventing these adverse events without interfering with the anti-cancer response. So we will usually try to use agents that are administered topically, or that have a different mechanism of action of the anti-cancer drug, so that there is no interference with the anti-tumor benefit. In addition, it’s also important to remember that many studies have shown that the appearance of adverse events appears to correlate with the response to the anti-cancer therapy, so it is precisely patients with adverse events that we should try to treat so that they can stay on therapy and live longer.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More